8月21日，恒瑞医药盘中下跌3.18%，报48.06港元，成交额8345.8万港元，延续前一交易日跌势。
消息面上，公司8月19日晚间披露半年报，营业收入154.56亿元，同比下降1.94%；扣非归母净利润37.30亿元，同比大幅下滑12.71%；经营活动现金流净额19.87亿元，同比骤降53.8%。虽然创新药销售收入88.09亿元同比增长16.4%，但仿制药收入同比下滑16.07%，对外许可收入同比降28.6%，主业盈利质量明显承压。尽管公司同步推出10亿至20亿元回购计划及员工持股方案，但市场对业绩放缓的担忧仍在持续释放。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.